Literature DB >> 826971

Serum dopamine-beta-hydroxylase in psychiatric patients and normals. Effect of d-amphetamine and haloperidol.

E S Markianos, I Nyström, H Reichel, N Matussek.   

Abstract

Serum dopamine-beta-hydroxylase activity was estimated in groups of normals and of psychiatric patients, using a thin layer radiochromatographic method. The percentage of patients with schizophrenic and with depressive symptomatology was higher in the population with high enzyme activities. In addition, d-amphetamine given to normals caused an increase in the serum activity while haloperidol caused the opposite effect. The activity in serum is interpreted as a loss in the enzyme from the place it acts physiologically, with possible influence on the noradrenaline synthesis rate.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 826971     DOI: 10.1007/BF00426842

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

1.  Changes in serum dopamine-beta-hydroxylase activity during group psychotherapy.

Authors:  S Silbergeld; R W Manderscheid; P H O'Neill; F Lamprecht; L K Ng
Journal:  Psychosom Med       Date:  1975 Jul-Aug       Impact factor: 4.312

Review 2.  DOPAMINE-BETA-HYDROXYLASE.

Authors:  S KAUFMAN; S FRIEDMAN
Journal:  Pharmacol Rev       Date:  1965-06       Impact factor: 25.468

3.  Serum dopamine beta-hydroxylase: assay and enzyme properties.

Authors:  E S Markianos; I E Nyström
Journal:  Z Klin Chem Klin Biochem       Date:  1975-07

4.  The antagonism of amphetamine-induced symptomatology by a neuroleptic.

Authors:  B Angrist; H K Lee; S Gershon
Journal:  Am J Psychiatry       Date:  1974-07       Impact factor: 18.112

5.  The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs.

Authors:  S H Snyder; K M Taylor; J T Coyle; J L Meyerhoff
Journal:  Am J Psychiatry       Date:  1970-08       Impact factor: 18.112

6.  Dopamine-norepinephrine: another regulatory step of norepinephrine synthesis in central noradrenergic neurons.

Authors:  A M Thierry; G Blanc; J Glowinski
Journal:  Eur J Pharmacol       Date:  1971-05       Impact factor: 4.432

7.  Plasma dopamine- -hydroxylase activity. Elevation in man during cold pressor test and exercise.

Authors:  G F Wooten; P V Cardon
Journal:  Arch Neurol       Date:  1973-02

8.  The activity of dopamine-beta-hydroxylase and methionine-activating enzyme in blood of schizophrenic patients.

Authors:  D L Dunner; C K Cohn; R M Weinshilboum; R J Wyatt
Journal:  Biol Psychiatry       Date:  1973-06       Impact factor: 13.382

9.  Dopamine-beta-hydroxylase deficits in the brains of schizophrenic patients.

Authors:  C D Wise; L Stein
Journal:  Science       Date:  1973-07-27       Impact factor: 47.728

10.  A new dopamine- -hydroxylase inhibitor: effects on the noradrenaline concentration and on the action of L-DOPA in the spinal cord.

Authors:  N E Andén; K Fuxe
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

View more
  3 in total

1.  Genotype-controlled analysis of serum dopamine β-hydroxylase activity in civilian post-traumatic stress disorder.

Authors:  Yi-lang Tang; Wenbiao Li; Kristina Mercer; Bekh Bradley; Charles F Gillespie; Robert Bonsall; Kerry J Ressler; Joseph F Cubells
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-08-22       Impact factor: 5.067

2.  The activities of brain dopamine-beta-hydroxylase and catechol-O-methyl transferase in schizophrenics and controls.

Authors:  A J Cross; T J Crow; W S Killpack; A Longden; F Owen; G J Riley
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

3.  A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders.

Authors:  C Hess; A Reif; A Strobel; A Boreatti-Hümmer; M Heine; K-P Lesch; C P Jacob
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.